Business Overview: Fennec Pharmaceuticals Inc. (NASDAQ: FENC)

---

Executive Summary

Fennec Pharmaceuticals Inc. is a British Columbia-incorporated, Research Triangle Park (North Carolina)-headquartered specialty pharmaceutical company. It operates as a "virtual" drug company — it owns no manufacturing plants and relies entirely on contract manufacturers — built around a single approved product: PEDMARK (sodium thiosulfate injection), the first and only FDA-approved therapy to reduce the risk of permanent hearing loss (ototoxicity) caused by cisplatin chemotherapy in pediatric cancer patients.

Fennec matters as a rare example of a true single-product pharma with a durable, multi-layered legal moat around that one product, now scaling internationally through a European partnership. FY2025 product sales reached $44.6 million, up 50% year-over-year, while the company still posted a net loss of $10.1 million as it continues to fund international expansion and litigation defense of its exclusivity.

---

1. Core Business Model & How They Work

Fennec sells PEDMARK directly in the U.S. and earns milestone/royalty economics internationally through a licensing partner, rather than building its own global commercial infrastructure.

 Contract manufacturers  ➡️  PEDMARK (U.S.):           PEDMARQSI (EU/UK/ANZ):
 (virtual model, no          Fennec direct sales        Licensed to Norgine (March 2024)
 owned plants)               force + "Fennec HEARS"      — Fennec received ~$43M upfront,
                             patient support program      eligible for ~$230M in milestones
                                                          + tiered double-digit-to-mid-20s%
                                                          royalties
                                                                │
                                                                ▼
                                                   Turkey/GCC: distribution agreement
                                                   with Inpharmus (2025)

---

2. Business Segments

Fennec is a single-product company and does not report business segments; its only commercial asset is sodium thiosulfate (PEDMARK/PEDMARQSI) for chemotherapy-induced ototoxicity.

---

3. Product Portfolio

---

4. Competitive Landscape

Fennec states plainly that no other commercially available agent reduces platinum-related hearing loss, making its direct competitive set unusually narrow. The real competitive threat is compounded sodium thiosulfate, prepared by 503A/503B compounding pharmacies — a cheaper, unapproved alternative that can substitute for PEDMARK outside of its patent and exclusivity protections. Earlier-stage or preclinical candidates (amifostine, D-methionine, SPI-3005, DB-020) represent longer-horizon, unproven competitive risks rather than immediate threats.

                 Regulatory status
                         │
   FDA/EMA-approved,     │
   patent-protected  ●PEDMARK/PEDMARQSI
                         │
   Compounded/off-label ─┼─ Approved/branded
   (cheap, unapproved)   │
                         │
         ● Compounded STS
       (503A/503B pharmacies)

---

5. Strategic Strengths & Risks

Strengths / moat sources:

• Layered legal exclusivity: Orange Book patents covering formulation/methods of use run to 2039 (plus a newly issued U.S. patent, "US '026," also expiring July 2039); U.S. Orphan Drug Exclusivity runs to September 20, 2029; EU pediatric exclusivity (PUMA) runs to May 26, 2033.
• Litigation resolved in Fennec's favor: Cipla's Paragraph IV generic challenge was settled in March 2026, with Cipla barred from entering the market before September 1, 2033 (absent certain triggers) — removing the nearest-term generic threat.
• Only approved product in its category, giving it real commercial and clinical-guideline leverage in pediatric oncology centers.
• High-margin international expansion via Norgine without Fennec having to build its own EU sales infrastructure.

Risks (named, not generic):

• Single-product concentration: 100% of revenue depends on PEDMARK/PEDMARQSI; any safety, supply, or competitive issue with this one product directly threatens the entire business.
• Compounded sodium thiosulfate remains available under 503A/503B pharmacy rules and is likely materially cheaper — an ongoing, not time-limited, substitution risk that patents don't fully solve.
• Partner execution risk: Fennec has not yet received any of the ~$230 million in potential Norgine milestone payments, meaning a meaningful part of the long-term economic case depends on Norgine's commercial execution in Europe.
• Small addressable population: the company estimates only ~2,157 U.S. and ~1,250 European cisplatin-treated pediatric patients per year fall within the PEDMARK market, which caps the revenue ceiling for the category regardless of execution.

---

6. Financial Overview

---

7. Summary Conclusion

Fennec Pharmaceuticals is a focused, single-product specialty pharma whose moat is almost entirely legal and regulatory: a multi-layered stack of Orange Book patents, orphan exclusivity, EU pediatric exclusivity, and a favorable Cipla settlement that collectively push out meaningful branded generic competition into the early 2030s. That moat does not, however, fully neutralize the compounded-pharmacy substitution risk that exists for as long as PEDMARK remains on patent and priced at a premium. With growth now also depending on Norgine's European execution and a structurally small patient population capping the category's revenue ceiling, the business is best understood as a durable royalty-and-direct-sales franchise in a narrow therapeutic niche rather than a broad platform story.